First-of-kind Guillain-Barré drug switches off part of immune system
A treatment that turns off the bit of the immune system that goes haywire in Guillain-Barré syndrome may be the first targeted therapy approved for the autoimmune condition
A treatment that turns off the bit of the immune system that goes haywire in Guillain-Barré syndrome may be the first targeted therapy approved for the autoimmune condition